Certificate of Analysis for NR-52199

Acinetobacter baumannii, Strain MRSN 15129

Catalog No. NR-52199

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 15129 was isolated in 2012 from a human respiratory sample in South America as part of a global surveillance program. *A. baumannii*, strain MRSN 15129 was deposited as sensitive to amikacin, ceftazidime, colistin, imipenem, meropenem and ampicillin/sulbactam, intermediately resistant to ceftriaxone, cefepime and tobramycin and resistant to ciprofloxacin, gentamicin, trimethoprim/sulfamethoxazole, levofloxacin and tetracycline. NR-52199 lot 70056285 was produced by inoculation of BEI Resources seed lot 70040797 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70056285 **Manufacturing Date: 20OCT2022**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream
Growth at 44°C ± 2°C[1] 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Motile
VITEK® MS (MALDI-TOF)	*A. baumannii*	*A. baumannii* (99.9%)
Antibiotic Susceptibility Profile[2,3]		
Amikacin	Sensitive	Sensitive (8 µg/mL)
Ampicillin/sulbactam	Sensitive	Sensitive (0.75 µg/mL)
Cefepime	Intermediate	Sensitive (8 µg/mL)[4]
Ceftriaxone	Intermediate	Intermediate (16 µg/mL)
Ceftazidime	Sensitive	Sensitive (4 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Colistin	Sensitive	Sensitive (0.125 µg/mL)
Gentamicin	Resistant	Intermediate (4 to 6 µg/mL)[5]
Imipenem	Sensitive	Sensitive (0.38 µg/mL)
Levofloxacin	Resistant	Resistant (8 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)[5]
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1490 base pairs)	≥ 99% sequence identity to *A. baumannii*, strain MRSN 15129 (GenBank: VHGR01000048.1)	99.9% sequence identity to *A. baumannii*, strain MRSN 15129 (GenBank: VHGR01000048.1)
Purity 12 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52199

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

[1]Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus and A. pittii*, which do not grow at 44°C.
[2]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[3]Antibiotic susceptibility was tested using a combination of VITEK®2 GN81, Sensititre™ GNX2F AST and E-test strips.
[4]The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.
[5]*A. baumannii*, strain MRSN 15129 was deposited as being resistant to gentamicin. Repeated antibiotic susceptibility testing determined that for strain MRSN 15129, the gentamicin MICs are 4 µg/mL and 6 µg/mL, which are interpreted as sensitive and Intermediate, respectively.
[6]*A. baumannii*, strain MRSN 15129 was deposited as being intermediately resistant to tobramycin, but showed a MIC of 4 µg/mL (interpreted as sensitive) for lot 70040796 during QC testing. Testing was performed in duplicate

/Sonia Bjorum Brower/
Sonia Bjorum Brower 07 SEP 2023
Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898